Results 301 to 310 of about 166,368 (358)
, 2016 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Allogeneic Stem Cell Transplantation
Nihon rinsho. Japanese journal of clinical medicine, 2002Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571.
Mary J. Laughlin, Hillard M. Lazarus
openaire +3 more sources
Allogeneic Stem Cell Transplantation
Transplantation Proceedings, 2005Allogeneic stem cell transplantation (HSCT) requires the harvest of an adequate number of stem cells (SC) from a histocompatible donor and their infusion into a patient following a conditioning regimen. During the past 35 years, the role of HSCT has changed from an experimental procedure for terminally ill patients to a curative treatment.
BOSI, ALBERTO, BARTOLOZZI B, GUIDI S.
openaire +3 more sources
Allogeneic blood stem cell transplantation
European Journal of Cancer, 2009The development of haematopoietic blood stem cell transplantation after World War II was stimulated by the concept of having an efficient treatment against irradiation damage after the military use of nuclear weapons and after accidents in nuclear plants.
Gerhard, Ehninger, Martin, Bornhäuser
openaire +2 more sources
Allogeneic Hematopoietic Stem Cell Transplantation
Therapeutic Apheresis and Dialysis, 2003Abstract: More than 30 years have passed since the first clinical application of allogeneic bone marrow transplantation to treat hematological diseases. In recent years, the availability of peripheral blood and cord blood as additional sources of stem cells other than bone marrow has expanded the applicability of hematopoietic stem cell transplantation.
Shunro, Kai, Hiroshi, Hara
openaire +2 more sources
Allogeneic stem-cell transplantation for myelofibrosis
Current Opinion in Hematology, 2017Purpose of review Allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only curative therapy for myelofibrosis. The number of HSCTs performed for this indication has been steadily increasing over the past years, even after the approval of the Janus kinase (JAK) inhibitor, ruxolitinib.
Noa, Lavi +2 more
openaire +2 more sources
Nonablative allogeneic hematopoietic stem cell transplantation
Current Opinion in Oncology, 2001During the past few years there has been an explosion of knowledge in nonablative allogeneic stem cell transplantation. This approach to transplantation relies more on the creation of "immunologic space" for engraftment rather than the more traditional approach of creating "physical space" by the application of either intensive radiation or chemical ...
R D, Dansey, R D, Baynes
openaire +2 more sources
Allogeneic Stem Cell Transplantation
2017Allogeneic stem cell transplantation in malignant diseases has evolved as a treatment option for patients with otherwise incurable diseases. The principle of this treatment is a significant tumor reduction by pretransplant chemotherapy or irradiation and immunological consolidation by various effector cells of the adaptive as well as of the innate ...
Patrick Schlegel +3 more
openaire +1 more source
Innovations in allogeneic stem-cell transplantation
Seminars in Hematology, 2000Allogeneic bone marrow transplantation (BMT) is associated with prolonged periods of neutropenia and thrombocytopenia, which can lead to severe infections and bleeding complications. Transplantation-related side effects might be ameliorated by use of cytokine-mobilized peripheral blood progenitor cells (PBPC) Instead of bone marrow.
J F, DiPersio +6 more
openaire +2 more sources